OncoMatch/Clinical Trials/NCT06762132
A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia
Is NCT06762132 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies CD33 CAR T-cells for acute myeloid leukemia.
Treatment: CD33 CAR T-cells — A Clinical Study on the Safety and Effectiveness of targeting CD33 CAR-T Cell in the treatment of Relapsed/Refractory Acute Myeloid Leukemia
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: CD33 overexpression (>80%)
Disease stage
Required: Stage RELAPSED, REFRACTORY (2016 WHO classification; Chinese Guidelines for the Diagnosis and Treatment of relapsed and refractory acute myeloid leukemia (2017 edition))
Complies with the 2016 WHO classification for AML diagnosis and meets the diagnostic criteria for recurrence and refractory acute myeloid leukemia in the "Chinese Guidelines for the Diagnosis and Treatment of relapsed and refractory acute myeloid leukemia (2017 edition)"
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard protocol treatment — induction
initial treatment cases that have failed to respond to two courses of standard protocol treatment
Cannot have received: gene therapy
Before using any gene therapy products
Lab requirements
Kidney function
serum creatinine ≤ 176.8 μmol / l
Liver function
total bilirubin ≤ 51 μmol / l, alt and ast ≤ 3 times of the upper limit of normal value
Cardiac function
echocardiography shows left ventricular ejection fraction (lvef) ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify